Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.
Recent comments
1 week 6 days ago
6 weeks 5 hours ago
7 weeks 15 hours ago
7 weeks 19 hours ago
28 weeks 1 day ago
32 weeks 2 days ago
33 weeks 6 days ago
34 weeks 5 hours ago
46 weeks 2 days ago
52 weeks 8 hours ago